184
Views
9
CrossRef citations to date
0
Altmetric
Hypothesis

Clozapine As Transformative Treatment In Bipolar Patients

ORCID Icon & ORCID Icon
Pages 2901-2905 | Published online: 09 Oct 2019

References

  • American Psychiatric Association, DSM-5 Task Force. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. Arlington, VA: American Psychiatric Publishing, Inc; 2013.
  • Ferrari AJ, Stockings E, Khoo JP, et al. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. Bipolar Disord. 2016;18(5):440–450. doi:10.1111/bdi.1242327566286
  • Nielsen J, Kane JM, Correll CU. Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study. Bipolar Disord. 2012;14:863–869. doi:10.1111/bdi.1201823107278
  • Chang JS, Ha KS, Young Lee K, Sik Kim Y, Min Ahn Y. The effects of long-term clozapine add-on therapy on the rehospitalization rate and the mood polarity patterns in bipolar disorders. J Clin Psychiatry. 2006;67:461–467. doi:10.4088/JCP.v67n031816649834
  • Li X-B, Tang Y-L, Wang C-Y, de Leon J. Clozapine for treatment resistant bipolar disorder: a systematic review. Bipolar Disord. 2015;17:235–247. doi:10.1111/bdi.2015.17.issue-325346322
  • Green AI, Tohen M, Patel JK, et al. Clozapine in the treatment of refractory psychotic mania. Am J Psychiatry. 2000;157:982–986. doi:10.1176/appi.ajp.157.6.98210831480
  • Banov MD, Zarate CA Jr, Tohen M, et al. Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up. J Clin Psychiatry. 1994;55:295–300.8071290
  • Calabrese JR, Kimmel SE, Woyshville MJ, et al. Clozapine for treatment-refractory mania. Am J Psychiatry. 1996;153:759–764. doi:10.1176/ajp.153.6.7598633686
  • Calabrese JR, Meltzer HY, Markovitz PJ. Clozapine prophylaxis in rapid cycling bipolar disorder. J Clin Psychopharmacol. 1991;11:396–397. doi:10.1097/00004714-199112000-000261770164
  • Chen CK, Shiah I-S, Yeh C-B, Mao W-C, Chang -C-C. Combination treatment of clozapine and topiramate in resistant rapid‐cycling bipolar disorder. Clin Neuropharmacol. 2005;28:136–138. doi:10.1097/01.wnf.0000169731.93065.ef15965313
  • Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495–553. doi:10.1177/026988111663654526979387
  • Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14:154–219. doi:10.3109/15622975.2013.77055123480132
  • Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord. 2009;11:225–255. doi:10.1111/j.1399-5618.2009.00672.x19419382
  • Poon SH, Sim K, Baldessarini RJ. Pharmacological approaches for treatment-resistant bipolar disorder. Curr Neuropharmacol. 2015;13(5):592–604. Published online 2015 September. doi:10.2174/1570159X1366615063017195426467409
  • Meltzer HY, Alphs L, Green AI, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82–91. doi:10.1001/archpsyc.60.1.8212511175
  • Hennen J, Baldessarini RJ. Reduced suicidal risk during treatment with clozapine: meta-analysis. Schizophrenia Res. 2005;73:139–145. doi:10.1016/j.schres.2004.05.015
  • Ciapparelli A, Dell’Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry. 2000;61:329–334. doi:10.4088/JCP.v61n050210847306
  • Carter TD, Mundo E, Parikh SV, Kennedy JL. Early age at onset as a risk factor for poor outcome of bipolar disorder. J Psychiatr Res. 2003;37:297–303. doi:10.1016/S0022-3956(03)00052-912765852
  • Meltzer HY, Anand R, Alphs L. Reducing suicide risk in schizophrenia: focus on the role of clozapine. CNS Drugs. 2000;14:355–365. doi:10.2165/00023210-200014050-00003
  • Vangala VR, Brown ES, Suppes T. Clozapine associated with decreased suicidality in bipolar disorder: a case report. Bipolar Disord. 1999;1:123–124.11252659
  • Wilkowska A, Wiglusz MS, Cubała WJ. Clozapine in treatment-resistant bipolar disorder with suicidality. Three case reports. Front Psychiatry. 2019;10:520. doi:10.3389/fpsyt.2019.0044831379632
  • Baldessarini RJ, Pompili M, Tondo L. Suicide in bipolar disorder: risks and management. CNS Spectr. 2006;11:465–471. doi:10.1017/s109285290001468116816785
  • Goodwin FK, Jamison KR. Manic-Depressive Illness. New York: Oxford University Press; 1990.
  • Frogley C, Taylor D, Dickens G, Picchioni M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol. 2012;15:1351–1371. doi:10.1017/S146114571100201X22339930
  • Kowatch R, Suppes T, Gilfillan SK, et al. Clozapine treatment of children and adolescents with bipolar disorder and schizophrenia: a clinical case series. J Child Adolesc Psychopharmacol. 1995;5:241–253. doi:10.1089/cap.1995.5.241
  • Brunette M, Dawson R, O’Keefe CD, et al. Clozapine vs. other antipsychotics for schizophrenia and co-occuring cannabis use disorder. Schizophr Bull. 2011;37:297.
  • Chau DT, Gulick D, Xie H, Dawson R, Green AI. Clozapine chronically suppresses alcohol drinking in Syrian golden hamsters. Neuropharmacology. 2010;58:351–356. doi:10.1016/j.neuropharm.2009.10.00619895824
  • Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003;60:81–85. doi:10.1016/S0920-9964(02)00231-112505141
  • Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol. 2000;20:94–98. doi:10.1097/00004714-200002000-0001610653215
  • Zhornitsky S, Rizkallah E, Pampoulova T. Antipsychotic agents for the treatment of substance use disorders in patients with and without comorbid psychosis. J Clin Psychopharmacol. 2010;30:417–424. doi:10.1097/JCP.0b013e3181e7810a20631559
  • Stahl SM. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Application. 4th ed. Cambridge: Cambridge University Press; 2013.
  • Marx CE, Shampine LJ, Duncan GE, et al. Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? Pharmacol Biochem Behav. 2006;84:598–608. doi:10.1016/j.pbb.2006.07.02616962649
  • Leveque JC, Macías W, Rajadhyaksha A, et al. Intracellular modulation of NMDA receptor function by antipsychotic drugs. J Neurosci. 2000;20:4011–4020. doi:10.1523/JNEUROSCI.20-11-04011.200010818136
  • Spivak B, Shabash E, Sheitman B, Weizman A, Mester R. The effects of clozapine vs. haloperidol on measures of impulsive aggression and suicidality in chronic schizophrenia patients: an open, nonrandomized, 6-month study. J Clin Psychiatry. 2003;64:755–760. doi:10.4088/JCP.v64n070312934974
  • Fukuyama K, Kato R, Murata M, Shiroyama T, Okada M. Clozapine normalizes a glutamatergic transmission abnormality induced by an impaired NMDA receptor in the thalamocortical pathway via the activation of a group III metabotropic glutamate receptor. Biomolecules. 2019;9:234. doi:10.3390/biom9060234
  • Park SW, Lee JG, Ha EK, et al. Differential effects of aripiprazole and haloperidol on BDNF-mediated signal changes in SH-SY5Ycells. Eur Neuropsychopharmacol. 2009;19(5):356–362. doi:10.1016/j.euroneuro.2008.12.01219196496
  • Maragnoli ME, Fumagalli F, Gennarelli M, Racagni G, Riva MA. Fluoxetine and olanzapine have synergistic effects in the modulation of fibroblast growth factor 2 expression within the rat brain. Biol Psychiatry. 2004;55(11):1095–1102. doi:10.1016/j.biopsych.2004.02.00315158429
  • Aringhieri S, Kolachalam S, Gerace C, et al. Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: role of 5-HT2A receptor agonism. Eur Neuropsychopharmacol. 2017;27(4):383–398. doi:10.1016/j.euroneuro.2017.02.00528283227
  • Alessandro G, Erbo D, Grayson DR. Epigenetic basis of clozapine action. J Drug Des Res. 2017;4(6):1055.29644342
  • Matrisciano F, Tueting P, Dalal I, et al. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology. 2013;68:184–194. doi:10.1016/j.neuropharm.2012.04.01322564440
  • Dong E, Tueting P, Matrisciano F, Grayson DR, Guidotti A. Behavioral and molecular neuroepigenetic alterations in prenatally stressed mice: relevance for the study of chromatin remodeling properties of antipsychotic drugs. Transl Psychiatry. 2016;6:e711.
  • Dong E, Locci V, Gatta E, Grayson DR, Guidotti A. N-Phthalyl-l-Tryptophan (RG108), like Clozapine (CLO), induces chromatin remodeling in brains of prenatally stressed mice. Mol Pharmacol. 2019;95(1):62–69. doi:10.1124/mol.118.11341530397000
  • Aoyama Y, Mouri A, Toriumi K, et al. Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor. Int J Neuropsychopharmacol. 2014;17:723–737. doi:10.1017/S146114571300146624345457
  • Kinoshita M, Numata S, Tajima A, et al. Effect of clozapine on DNA methylation in peripheral leukocytes from patients with treatment-resistant schizophrenia Int J Mol Sci. 2017;18:632. doi:10.3390/ijms18030632
  • Kouter K, Zupanc T, Paska V. A genome-wide DNA methylation in suicide victims revealing impact on gene expression. J Affect Disord. 2019;15(253):419–425. doi:10.1016/j.jad.2019.04.077
  • Nakazawa T, Kikuchi M, Ishikawa M, et al. Differential gene expression profiles in neurons generated from lymphoblastoid B cell line-derived iPS cells from monozygotic twin cases with treatment-resistant schizophrenia and discordant responses to clozapine. Schizophr Res. 2017;181:75–82. doi:10.1016/j.schres.2016.10.01228277309
  • Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical antipsychotic trials of intervention effectiveness I effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223. doi:10.1056/NEJMoa05168816172203
  • Lewis DA, Gonzalez-Burgos G. Pathophysiologically based treatment interventions in schizophrenia. Nat Med. 2006;12:1016–1022. doi:10.1038/nm147816960576
  • Critchlow HM, Maycox PR, Skepper JN, Krylova O. Clozapine and haloperidol differentially regulate dendritic spine formation and synaptogenesis in rat hippocampal neurons. Mol Cell Neurosci. 2006;32(4):356–365. doi:10.1016/j.mcn.2006.05.00716844384
  • Ozdemir H, Ertugrul A, Basar K, Saka E. Differential effects of antipsychotics on hippocampal presynaptic protein expressions and recognition memory in a schizophrenia model in mice. Progress in Neuro-psychopharmacology & Biological Psychiatry. 2012;39(1):62–68.
  • Halene TB, Kozlenkov A, Jiang Y, et al. NeuN+ neuronal nuclei in non-human primate prefrontal cortex and subcortical white matter after clozapine exposure. Schizophr Res. 2016;170:235–244. doi:10.1016/j.schres.2015.12.01626776227
  • Maletic V, Raison C. Integrated neurobiology of bipolar disorder. Front Psychiatry. 2014;5:98. doi:10.3389/fpsyt.2014.0009825202283
  • Miller S, Dell’Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord. 2014;169(Suppl 1):S3–S11. doi:10.1016/S0165-0327(14)70003-525533912
  • Faulkner E, Spinner DS, Ringo M, Carroll M. Are global health systems ready for transformative therapies? Value Health. 2019;22(6):627–641. doi:10.1016/j.jval.2019.04.191131198179